The therapeutic role of Norphyl (Choline Theophyllinate) is commonly used to support the easing of symptoms related to physical discomfort stemming from constricted airways in chronic lung diseases. The medication may assist with managing symptoms that create noticeable physiological strain and supports general well-being during symptomatic phases.

This medication is applied across domains where additional symptomatic support is needed. It plays a role in managing conditions characterized by periods of heightened symptoms such as bronchial asthma, Chronic Obstructive Pulmonary Disease (COPD), chronic bronchitis, and pulmonary emphysema.

---

Key Therapeutic Focus

Norphyl provides supportive relief by targeting symptoms of increased muscular activity, specifically bronchial spasm, which causes wheezing and severe chest tightness. This application assists with easing the overall burden of obstructive manifestations and may help patients cope more steadily with symptom fluctuations during episodes of heightened discomfort. It is particularly relevant for easing symptoms that interfere with daily functioning, including those that cluster as nocturnal asthma. This use supports the patient in maintaining a sense of stability and is commonly used to help with episodic breathing difficulty.

---

Quick Fact: Symptomatic Support for Airway Obstruction Norphyl helps to manage the symptomatic discomfort of chest tightness and shortness of breath associated with chronic conditions by contributing to the easing of the overall symptom load.

Regulatory References

1. NIH MedlinePlus overview of Theophylline

The eligibility for Norphyl (Choline Theophyllinate) is determined by regulatory bodies based on specific patient populations and concurrent health conditions that impact how the drug is processed by the body.

Who Must Not Use Norphyl (Contraindications)

Norphyl is contraindicated for individuals with a known history of hypersensitivity or allergic reaction to Theophylline, Choline Theophyllinate, or any other xanthine derivative (such as caffeine or aminophylline).

---

Populations Requiring Restricted or Conditional Use

Use of this medicine requires caution and close medical monitoring in populations where the drug's clearance is significantly altered, including:

Population Group / Condition	Regulatory Restriction Basis
Severe Hepatic Impairment (e.g., cirrhosis, acute hepatitis)	Clearance is documented as reduced by 50% or more.
Neonates (Term and Premature Infants)	Highly variable and significantly reduced drug clearance; increased risk of accumulation.
Older Adults (>60 years)	Reduced clearance compared to younger adults; increased risk of toxicity.
Congestive Heart Failure or Cor Pulmonale	Documented reduction in drug clearance.
Active Peptic Ulceration or Seizure Disorders	Use may exacerbate these pre-existing conditions.
Pregnancy (3rd Trimester)	Clearance is documented as decreased. FDA Category C status applies (conditional use).
Sustained High Fever (ge 102 F)	Fever temporarily reduces drug clearance, necessitating monitoring.

Standard use is established for most adults and adolescents who do not have the listed risk factors, though individualized monitoring may still be necessary due to the drug's narrow therapeutic window.

Interactions with other medicines and products

Official regulatory information organizes the interaction profile of Norphyl primarily by effects on its clearance (removal from the body).

Interaction Type	Examples of Interacting Medicines and Products
Decreased Clearance (Increased Norphyl Levels)	Cimetidine, Erythromycin, Interferon, Quinolone antibiotics (e.g., Enoxacin, Ciprofloxacin), Oral contraceptives, Viloxazine, Riociguat.
Increased Clearance (Decreased Norphyl Levels)	CYP450 inducers (e.g., Phenobarbital, Carbamazepine, Phenytoin, Rifampin), St. John's Wort, tobacco or marijuana smoking.
Additive Pharmacologic Effects	Other methylxanthines (e.g., Caffeine-containing foods/beverages), Beta-agonists (e.g., Albuterol/Salbutamol), Adenosine.

Co-administration with Riociguat and Viloxazine is generally not recommended as a significant interaction-related restriction. The primary mechanistic basis for the majority of clinically significant drug interactions is the change in the drug's metabolism via the Cytochrome P450 1A2 (CYP1A2) enzyme system. Products that inhibit this system can lead to dangerously high drug levels, while inducers can lead to sub-therapeutic levels.

Changes in a patient’s condition, such as fever (102 F or higher for 24 hours), or changes in smoking status or diet require timely monitoring of drug levels. Use of the drug with certain medicinal products, including halothane and ephedrine, may also increase the risk of certain adverse effects.

Theophylline (the active component in Norphyl) affects physiological processes systemically by engaging three core mechanistic domains.

---

Enzyme Inhibition for Airway Relaxation

This domain involves the molecule acting as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4. By blocking PDE, the drug increases the concentration of the crucial messenger cyclic AMP (cAMP) within target cells, leading to a phosphorylation cascade that reduces calcium concentrations in bronchial smooth muscle, which leads to physical airway relaxation.

---

Receptor Antagonism and Anti-Inflammatory Modulation

A second critical domain is the drug's activity as a non-selective antagonist of Adenosine Receptors. This blocks signals that typically promote constriction and mediator release in the lungs, resulting in altered airway responsiveness. Additionally, the mechanism involves the restoration of Histone Deacetylase-2 (HDAC2) function, a process that suppresses the transcription of pro-inflammatory genes.

---

Systemic Engagement and Concentration Dependency

The mechanism is characterized by its non-selective engagement with targets across the body, resulting in both peripheral (smooth muscle) and central nervous system (CNS) activity that increases the drive to breathe. The full manifestation of its dual effects, including the separate anti-inflammatory action and the primary bronchodilator mechanism, is highly dependent on the amount of the drug present in the plasma, reflecting a mechanism constrained by concentration thresholds.

How to Use Norphyl (Choline Theophyllinate)

Norphyl, which delivers the active component Theophylline, is administered according to a highly structured protocol based on its intended use and formulation. This section details the official administration guidelines.

Administration Routes and Forms

Norphyl is primarily administered via the oral route for long-term maintenance therapy. However, the therapeutic component, Theophylline, is also available as an intravenous (IV) solution for controlled administration in acute clinical scenarios. Available dosage forms include conventional tablets, extended-release tablets, and the IV solution.

Dosing and Frequency Principles

Dosing is individualized and requires initial titration to achieve a specific therapeutic goal: a serum Theophylline concentration range typically between 10 to 15 mcg/mL. The maximum recommended adult dose is generally limited, often up to 600 mg per day (Theophylline equivalent).

• Extended-Release Forms: These are designed for once daily or twice daily administration to ensure sustained drug levels over time.
• Immediate-Release Forms: These are typically taken as divided doses every four to eight hours.

Administration Constraints and Adjustments

Correct physical handling is mandatory for the extended-release formulation. These tablets must be swallowed whole and must not be crushed, broken, or chewed to preserve the intended controlled-release mechanism. The medication can generally be taken with or without food.

Population-Specific Rules: Dosing requires careful adjustment for certain groups. Older adults typically require a lower maximum daily dose, and doses for pediatric patients are calculated based on age and weight, necessitating careful monitoring. The dose may also require adjustment in the presence of factors that slow the body's clearance of the drug, such as fever.

Research evidence / Overview of studies for Norphyl

Evidence for use in Bronchial Asthma (Chronic and Nocturnal)

Research has explored the use of Norphyl and its parent compound in individuals managing bronchial asthma, which is one of the conditions characterized by fluctuating or episodic manifestations. These studies monitored outcomes related to systemic or functional imbalance, specifically looking at how the function of the airways was measured over defined time intervals. The research included short-term Randomized Controlled Trials (RCTs) and older studies applied in populations of adults and children with stable chronic asthma. Researchers typically measured objective outcomes like the Forced Expiratory Volume in 1 second ( FEV1) and Peak Expiratory Flow Rate ( PEFR), which are outcomes measured by researchers to assess functional limitations. Findings describe patterns observed in the studies where measurements of functional lung capacity were reported during the observed period compared to baseline or a control group. The evidence contributing to understanding symptom patterns is often derived from studies with follow-up durations that were limited, meaning the reported outcomes were typically only short-term.

---

Evidence for use in Chronic Obstructive Pulmonary Disease (COPD)

Norphyl was also studied for use in patients with Chronic Obstructive Pulmonary Disease ( COPD), a condition marked by functional limitations. The research examined its role, often as an addition to standard inhaled medications. Research has explored various clinical outcomes, including changes in FEV1 measurements and outcomes capturing phases of heightened symptom activity, known as COPD exacerbations. Findings show patterns related to measurements of change in lung function over time intervals. However, when examining exacerbation rates, findings were mixed across studies, and some larger, contemporary trials did not report a significant statistical difference in the frequency of acute episodes when compared to patients receiving only standard care. The evidence highlights what is known—and what is still uncertain—about the findings related to acute COPD episodes.

---

Understanding the Evidence Quality and Gaps

The body of evidence includes trials that vary in design and scope. Much of the foundational evidence is older, and some key research explores the parent drug, Theophylline, rather than the specific Choline Theophyllinate salt. This means that evidence quality varies across studies. The major areas where certainty remains low include the long-term functional outcomes measured in both conditions and the inconsistent reports from research findings concerning COPD exacerbation frequency. Furthermore, dedicated research directly comparing the Choline Theophyllinate salt with the standard Theophylline compound is lacking. Research provides context about what has been observed so far, but it is clear that more research is ongoing to help contextualize how patients reported their experience and fill these known gaps.

Key Studies & References

1. Label: THEOPHYLLINE tablet, extended release - DailyMed (Reflecting regulatory data on Theophylline)

Common questions about Norphyl (FAQ)

---

Q: How do I know if the drug is working?

Official information indicates that the drug's effectiveness is often monitored through objective clinical measurements, such as improved forced expiratory volume in 1 second (FEV1), which measures lung function. Additionally, monitoring the amount of active drug in the bloodstream, known as the serum Theophylline concentration, is a key measurement used to help determine if drug levels remain in the therapeutic range.

---

Q: What should I do if I miss a dose?

Official product information suggests that if a dose is missed, it should be taken as soon as it is remembered, unless it is close to the next scheduled dose. If it is near the time for the next dose, the missed one should be skipped entirely. It is noted that a double dose should not be taken to compensate for a missed one.

---

Q: Is Norphyl safe for breastfeeding mothers?

Regulatory information indicates that the active component, Theophylline, can pass into human milk. Official guidance suggests the infant may require close monitoring for signs of drug effects, such as increased irritability. It is also noted that drug levels may be kept in the lower range of the therapeutic window when the active component is used during lactation.

---

Q: Can Norphyl cause weight loss or weight gain?

Official adverse reaction lists for the active ingredient primarily focus on gastrointestinal and nervous system side effects. While certain reports have mentioned 'weight gain,' it is not consistently featured on official lists of common adverse reactions, and its frequency is not well established.

---

Q: Can Norphyl cause mood changes or depression?

According to official documentation, the drug's central nervous system activity can cause common effects like restlessness and insomnia. Although major psychiatric disorders like depression are not routinely listed, related effects such as irritability are documented, reflecting the drug's stimulating effect.

How to Store and Dispose of Norphyl (Choline Theophyllinate)

Storage and disposal requirements for Norphyl are strictly defined in regulatory documents to maintain the product's stability and ensure safety.

Storage Requirement	Official Regulatory Statement
Temperature & Environment	Store in a cool and dry place.
Protection	The product must be protected from light.
Container Rule	Keep the container tightly closed.
Child Safety	The medication must be kept out of the reach of children.

To preserve the product's labeled shelf life, these conditions must be strictly followed. Do not use Norphyl after the expiry date printed on the packaging.

For disposal, unused or expired medication must be handled in accordance with local requirements and should not be discarded into household waste or wastewater, as per official guidance.